Cancer Innovation期刊

第1卷第1期 正式发布

▸Cancer Innovation是一本专注于肿瘤学，以及肿瘤学与工学、信息学、药学、生物学等多学科前沿交叉的期刊。

▸Cancer Innovation是一本高质量、同行评审、开放获取（Open Access）期刊，2024年前免收版面费。

▸ 2022年6月，Cancer Innovation第1卷第1期在线发布。

▸第1卷第1期在线网址：   

https://onlinelibrary.wiley.com/toc/27709183/2022/1/1

第1卷第1期(2022.6)

（▼ 点击图片阅读全文）

评论 ▏ Editorial

01

The inauguration of Cancer Innovation: Leading New Frontiers in Oncology, Building Human Health Community

(扫码/点击图片阅读全文)

临床指南 ▏ Clinical Guidelines

02

Expert consensus on the clinical application of antibody-drug conjugates in the treatment of malignant tumors (2021 edition)

Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association , Expert Committee for Monitoring the Clinical Application of Antitumor Drugs , Breast Cancer Expert Committee of National Cancer Quality Control Center , Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center

(点击图片阅读全文)

引用格式：

Ma F, Xu B. Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition). Cancer Innovation.2022;1–22.

https://doi.org/10.1002/cai2.8

03

Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer

The Society of Clinical Research of Oncology Medications of China Anticancer Association,Breast Cancer Expert Committee of National Cancer Quality Control Center,Boao Cancer Innovation Institute

(点击图片阅读全文)

引用格式：

Ma F, Xu B. Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer. Cancer Innovation .2022;1:25–54.

https://doi.org/10.1002/cai2.10

原创性研究 ▏ Original Articles

04

ATF4/TXNIP/REDD1/mTOR signaling mediates the antitumor activities of liver X receptor in pancreatic cancers

Zhikang Chen, Xiaobo Lai, Hui Ding, Aijun Zhang, Yufei Sun, Jianhua Ling, Paul J. Chiao, Zihua Chen, Xuefeng Xia

(点击图片阅读全文)

引用格式：

Chen Z, Lai X, Ding H,Zhang A, Sun Y, Ling J, et al. ATF4/TXNIP/REDD1/mTOR signaling mediates the antitumor activities of liver X receptor in pancreatic cancers. Cancer Innovation. 2022;1:55–69.

https://doi.org/10.1002/cai2.12

05

Genetic variants in XPD gene and glioma susceptibility in Chinese children: A multicenter case–control study

Yong-Ping Chen, Yuxiang Liao, Li Yuan, Xiao-Kai Huang, Ji-Chen Ruan, Hui-Ran Lin, Lei Miao, Zhen-Jian Zhuo

(点击图片阅读全文)

引用格式：

Chen Y‐P, Liao Y, YuanL, Huang X‐K, Ruan J‐C, Lin H‐R, et al. Genetic variants in XPD gene and glioma susceptibility in Chinese children: a multicenter case–control study. Cancer Innovation. 2022;1:70–79.

https://doi.org/10.1002/cai2.6

综述 ▏ Reviews

06

Application of informatics in cancer research and clinical practice: Opportunities and challenges

Na Hong, Gang Sun, Xiuran Zuo, Meng Chen, Li Liu, Jiani Wang, Xiaobin Feng, Wenzhao Shi, Mengchun Gong, Pengcheng Ma

(点击图片阅读全文)

引用格式：

Hong N, Sun G, Zuo X,Chen M, Liu L, Wang J, et al. Application of informatics in cancer research and clinical practice: opportunities and challenges. Cancer Innovation. 2022;1–12. 

https://doi.org/10.1002/cai2.9

07

Crosstalk between ferroptosis and stress—Implications in cancer therapeutic responses

Cheng Zhang, Jiao-jiao Yu, Chen Yang, Shuang Shang, Xiao-xi Lv, Bing Cui, Fang Hua

(点击图片阅读全文)

引用格式：

hang C, Yu J‐j, Yang C,Shang S, Lv X‐x, Cui B, et al. Crosstalk between ferroptosis and stress—implications in cancer therapeutic responses. Cancer Innovation. 2022;1:92–113.

https://doi.org/10.1002/cai2.7

病例报告 ▏ Case Report

08

Identification of novel somatic fusions of ERG-VEGFA, TMPRSS2-ERG, and VEGFA-TMPRSS2 in prostate cancer treated with anlotinib and androgen deprivation therapy: A case report

Qiuli Liu, Shuo Wang, Ze Wang, Peng Tang, Dianzheng Zhang, Weihua Lan, Jun Jiang

(点击图片阅读全文)

如何引用：

Liu Q, Wang S, Wang Z,Tang P, Zhang D, Lan W, et al. Identification of novel somatic fusions of ERG‐VEGFA,TMPRSS2‐ERG,

and VEGFA‐TMPRSS2 in prostate cancer treated with anlotinib and androgen deprivation therapy: a case report. Cancer Innovation. 2022;1–5.

https://doi.org/10.1002/cai2.11

关于期刊

Cancer Innovation《肿瘤创新（英文）》是清华大学出版社与 Wiley战略合作下出版的一本跨学科的开放获取（OA）英文期刊，也是博鳌肿瘤创新研究院的官方出版物。Cancer Innovation致力于发表基础研究和临床肿瘤学领域创新且具有重大意义的研究成果，并关注工学、信息学、药学、生物学等多学科交叉的肿瘤创新研究，肿瘤学与其他医学亚专科之间的跨专业融合研究及共病管理，肿瘤预防、诊断、治疗与管理的新观点、新理念、新方法、新模式等最新研究成果和创新产出。期刊力求涵盖全球肿瘤学专家关心的国际热点问题，方便国内外研究者更精准、更高效地发表自己新颖性研究成果；推广新理念，发展新技术，创用新模式，同时搭建国际肿瘤创新学术交流平台，助力全球健康一体化的发展。

Cancer Innovation荣誉主编由中国工程院院士、国家癌症中心/中国医学科学院肿瘤医院国家新药（抗肿瘤）临床研究中心（GCP中心）主任医师徐兵河院士，中国工程院院士、北京大学国际癌症研究院院长，北京大学健康医疗大数据国家研究院院长，教育部长江学者特聘教授詹启敏院士，以及中国工程院院士、中科院上海药物研究所研究员丁健院士共同担任，主编是国家癌症中心/中国医学科学院肿瘤医院内科治疗中心主任马飞教授。

期刊发表论文类型多元，包括Original Article, Review，Clinical Guideline，Technical Report，Case Rreport，Commentary，News，Editorial，Study Protocol与Meta-Analysis，并采用自由格式投稿的领先模式，减轻作者负担。此外，创刊初期2022年-2024年，Cancer Innovation免收文章出版费（APC）。

关于投稿

Cancer Innovation竭诚欢迎广大科研工作者、医生、研究生积极向期刊投稿！

官方主页：

https://onlinelibrary.wiley.com/journal/27709183

投稿系统：

https://mc.manuscriptcentral.com/cancerinnovation

联系我们：

Email:cancerinnovation@tup.tsinghua.edu.cn

了解医学  守护健康

欢迎点击下方公众号

更多医学相关内容为您呈现